// App-Quantinova.ai

: Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: liberty asthma quest Study

Researchers

Presenter

  • Alberto Papi

Principal Investigators

  • Ian D. Pavord

  • J. Mark Fitzgerald

  • Jonathan Corren

  • Philip Bardin

  • Hae Sim Park

  • Megan S. Rice

  • Yamo Deniz

  • Paul Rowe

  • Heribert Staudinger

  • Nikhil Amin

  • Marcella Ruddy

  • Neil M.H. Graham

  • Ariel Teper

Medical Centers

  • University Hospital Santa Anna, Ferrara, Italy,

  • Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom

  • UCLA David Geffen School of Medicine, Rheumatology, Los Angeles, United States of America

  • Monash University and Monash Medical Centre, Melbourne and Clayton, Australia

  • Ajou University, Suwon, Republic of Korea

  • Regeneron Pharmaceuticals - Tarrytown - United States of America

  • Sanofi US, Bridgewater, United States of America

Locations

  • Italy

  • United Kingdom

  • Canada

  • United States

  • Australia

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02414854

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved